Tirzepatide
Worth trying, BioHarmony verdict
BioHarmony score 6.1 out of 10
Tirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects. Jastreboff 2022 established major body-weight reduction in adults with obesity, Frias 2021 showed superiority to semaglutide 1 mg for type 2 diabetes glycemia, and…
Read full reportWhat is Tirzepatide?
Tirzepatide is a once-weekly injectable peptide pharmaceutical that activates both glucose-dependent insulinotropic polypeptide receptors and glucagon-like peptide-1 receptors. The practical effects are reduced appetite, improved glucose-dependent insulin secretion, altered glucagon signaling, delayed gastric emptying, and lower body weight. In the pivotal obesity program, Jastreboff 2022 showed substantial weight reduction versus placebo in adults with obesity or overweight without diabetes. In type 2 diabetes, Frias 2021 showed greater glycemic and weight effects than semaglutide 1 mg.
From the BioHarmony report, reviewed Sep 19, 2026.
Saved on this device only.
Safety watch-outs
- Persistent vomiting or dehydration
- Severe abdominal pain
- Blood in stool or black stool
- Symptoms of pancreatitis: severe upper abdominal pain radiating to back
- Right upper quadrant pain, fever, jaundice, or pale stools (gallbladder)
Full risk profile in the BioHarmony report.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (2)
Attributed viewpoints, separate from primary research.
- A Complete Guide To Using Tirzepatide PLUS My Advice for 2024 Hunter Williams,
- Tirzepatide and Creatine: Is This Combo Safe to Stack? Jay Campbell,
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
FDA lists approved tirzepatide products and warns that unapproved versions do not undergo FDA review for safety, effectiveness, or quality before marketing. FDA had received more than 730 adverse-event reports associated with compounded tirzepatide as of May 31, 2026.
Primary sources
- FDA's concerns with unapproved GLP-1 drugs used for weight loss U.S. Food and Drug Administration,
- Zepbound (tirzepatide) prescribing information DailyMed, U.S. National Library of Medicine,
Related peptides for weight & metabolic
- 6.0MOTS-cMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
- 6.0TesamorelinTesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for…
- 5.9Semaglutide (GLP-1 Agonist)Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds…
- 5.8CagrilintideCagrilintide (AM833) is a long-acting amylin receptor analogue that drove about 11.8 percent weight loss as monotherapy at 68 weeks in REDEFINE 1 per Garvey 2025, with…
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.